- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07298395
Studie van ENV-294 bij volwassenen met matige tot ernstige atopische dermatitis
Een fase 2, gerandomiseerd, dubbelblind, placebo-gecontroleerd, parallelgroep, 12-weken durend onderzoek om de werkzaamheid, veiligheid en farmacokinetiek van ENV 294 te evalueren bij volwassen deelnemers met matig tot ernstig constitutioneel eczeem
The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis.
The main questions it will answer are:
- Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294
- What medical problems do participants have when taking ENV-294
Participants will:
- Take drug ENV-294 or a placebo once every day for 12 weeks
- Visit the clinic every 2 to 4 weeks for checkups and tests
- Keep a diary of their symptoms and when they took their study drug
- Return to the clinic for the final study visit at approximately week 16
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Clinical Operations
- E-mail: env-294.clinicaltrials@enveda.com
Studie Locaties
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35244
- Werving
- Enveda Investigative Site
-
-
Arkansas
-
Hot Springs, Arkansas, Verenigde Staten, 71913
- Werving
- Enveda Investigative Site
-
-
California
-
Beverly Hills, California, Verenigde Staten, 90212
- Werving
- Enveda Investigative Site
-
Fremont, California, Verenigde Staten, 94538
- Werving
- Enveda Investigative Site
-
San Diego, California, Verenigde Staten, 92121
- Werving
- Enveda Investigative Site
-
San Diego, California, Verenigde Staten, 92123
- Werving
- Enveda Investigative Site
-
Santa Monica, California, Verenigde Staten, 90403
- Werving
- Enveda Investigative Site
-
West Hills, California, Verenigde Staten, 91307
- Werving
- Enveda Investigative Site
-
-
Florida
-
Fort Lauderdale, Florida, Verenigde Staten, 33308
- Werving
- Enveda Investigative Site
-
Miami, Florida, Verenigde Staten, 33175
- Werving
- Enveda Investigative Site
-
Miramar, Florida, Verenigde Staten, 33027
- Werving
- Enveda Investigative Site
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30327
- Werving
- Enveda Investigative Site
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60657
- Werving
- Enveda Investigative Site
-
-
Indiana
-
Clarksville, Indiana, Verenigde Staten, 47129
- Werving
- Enveda Investigative Site
-
New Albany, Indiana, Verenigde Staten, 47150
- Werving
- Enveda Investigative Site
-
West Lafayette, Indiana, Verenigde Staten, 47906
- Werving
- Enveda Investigative Site
-
-
Kentucky
-
Louisville, Kentucky, Verenigde Staten, 40217
- Werving
- Enveda Investigative Site
-
Louisville, Kentucky, Verenigde Staten, 40241
- Werving
- Enveda Investigative Site
-
-
Michigan
-
Auburn Hills, Michigan, Verenigde Staten, 48326
- Werving
- Enveda Investigative Site
-
Bay City, Michigan, Verenigde Staten, 48706
- Werving
- Enveda Investigative Site
-
Clinton Township, Michigan, Verenigde Staten, 48038
- Werving
- Enveda Investigative Site
-
Warren, Michigan, Verenigde Staten, 48088
- Werving
- Enveda Investigative Site
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89145
- Werving
- Enveda Investigative Site
-
-
New York
-
New York, New York, Verenigde Staten, 10029
- Werving
- Enveda Investigative Site
-
-
North Carolina
-
Wilmington, North Carolina, Verenigde Staten, 28405
- Werving
- Enveda Investigative Site
-
-
Ohio
-
Canton, Ohio, Verenigde Staten, 44718
- Werving
- Enveda Investigative Site
-
Mayfield Heights, Ohio, Verenigde Staten, 44124
- Werving
- Enveda Investigative Site
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, Verenigde Staten, 17011
- Werving
- Enveda Investigative Site
-
-
Texas
-
Arlington, Texas, Verenigde Staten, 76011
- Werving
- Enveda Investigative Site
-
Houston, Texas, Verenigde Staten, 77004
- Werving
- Enveda Investigative Site
-
San Antonio, Texas, Verenigde Staten, 78218
- Werving
- Enveda Investigative Site
-
-
Virginia
-
Norfolk, Virginia, Verenigde Staten, 23502
- Werving
- Enveda Investigative Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Have chronic atopic dermatitis that was diagnosed at least 12 months prior to the first study visit
-
Have moderate-to-severe AD at screening and baseline as defined by the following criteria:
- A vIGA score of 3 (moderate) or 4 (severe)
- EASI score of ≥16
- BSA ≥10%
- PP-NRS score of ≥4
-
Have had either a poor response or intolerance to topical treatments for atopic dermatitis (such as corticosteroids) within the past 6 months
-
Use a bland moisturizer at least daily
Exclusion Criteria:
- Current or recurrent medical conditions that could affect the study drug or study assessments
- Any illness that could impact participant safety or active infections
- Ongoing skin condition or large tattoos that would interfere with clinical assessment
- Clinically significant skin infection requiring treatment
- Clinically significant abnormal laboratory assessments at screening
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: ENV-294 Treatment Arm
ENV-294 will be administered to those participants randomized to the treatment arm. |
ENV-294 is an orally administered investigational drug supplied as tablets. Participants receive ENV-294 once daily by mouth for 12 weeks. |
|
Placebo-vergelijker: Placebo Arm
A placebo will be administered to those participants randomized to the placebo arm. |
Matching oral tablet that does not contain active drug. Administered once daily by mouth for 12 weeks under the same conditions as the investigational product. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
To evaluate the efficacy of ENV-294 compared to placebo on severity and extent of atopic dermatitis (AD)
Tijdsspanne: Baseline to Week 12
|
The effectiveness of ENV-294 compared with placebo will be assessed by the percent change in Eczema Area and Severity Index (EASI) score from the start of the study (Baseline) to Week 12 (Day 85). The EASI score measures the extent and severity of atopic dermatitis, with higher scores indicating more severe disease. |
Baseline to Week 12
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence and Severity of Adverse Events
Tijdsspanne: Baseline to Week 12
|
Number and seriousness of adverse events (AEs), serious adverse events (SAEs), and adverse events leading to discontinuation of study drug. |
Baseline to Week 12
|
|
EASI-75 Response
Tijdsspanne: Baseline to Week 12
|
Percentage of participants with at least 75% reduction from Baseline in Eczema Area and Severity Index (EASI) score. |
Baseline to Week 12
|
|
vIGA Response
Tijdsspanne: Baseline to Week 12
|
Proportion of participants who achieve a ≥2-point reduction from Baseline in validated Global Investigator Assessment (vIGA) score and a score of 0 or 1. |
Baseline to Week 12
|
|
Patient-Reported Outcomes
Tijdsspanne: Baseline to Week 12
|
Change and percent change in Peak Pruritus Numerical Rating Scale (PP-NRS). |
Baseline to Week 12
|
|
Patient-Reported Outcomes
Tijdsspanne: Baseline to Week 12
|
Change and percent change in Patient Oriented Eczema Measure (POEM). |
Baseline to Week 12
|
|
Pharmacokinetics of ENV-294
Tijdsspanne: Baseline to Week 12
|
Observed concentration values of ENV-294 at the times blood samples are collected. |
Baseline to Week 12
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Gurpreet Ahluwalia, PhD, Enveda Therapeutics, Inc.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- ENV-294-201
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Individual participant data (IPD) will not be shared. The data include sensitive health information that cannot be fully de-identified under current privacy standards, and the sponsor does not plan to make IPD available outside the study team. Summary results and aggregate data will be shared publicly as required by regulation.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .